Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734168 | 0.93 | KDM4E (0.46) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL734937 | 0.89 | POLA1 (0.56) | KDM4EPOLA1TAS1R3TAS1R1POLB | |
| SCHEMBL732905 | 0.87 | KDM4E (0.43) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL31098030 | 0.85 | KDM4E (0.57) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL9703289 | 0.84 | KDM4E (0.74) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL22315215 | 0.84 | KDM4E (0.74) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL3024229 | 0.84 | KDM4E (0.45) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL733738 | 0.83 | KDM4E (0.41) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL25398969 | 0.81 | KDM4E (0.48) | KDM4EPOLA1TAS1R3TAS1R1P2RY1 | |
| SCHEMBL889631 | 0.80 | KDM4E (0.53) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138330-B2 | Solid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite | SIGMA-ALDRICH CO. LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | SIGMA ALDRICH COMPANY (US) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | RNGTT, DUT, ADAR | KDM4E 1717/4885POLA1 52/4885TAS1R3 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.